Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Ming Wang

Showing results (361-370 of 367) with videos related to

Pageof 37
Sort By:
You have reached the last page of results.This site can display upto 367 results.
Acta Pharmacologica Sinica|July 21, 2015
IL-37b gene transfer enhances the therapeutic efficacy of mesenchumal stromal cells in DSS-induced colitis miceWei-qiang Wang, Kui Dong, Lu Zhou, et al.
Hepatobiliary & Pancreatic Diseases International : HBPD INT|June 15, 2016
Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure: a nationwide prospective multicenter study in ChinaJia-Jia Chen, Jian-Rong Huang, Qian Yang, et al.
Japanese Journal of Radiology|February 5, 2026
Intensity-modulated proton therapy for patients with unresectable giant (≥ 10 cm) hepatocellular carcinoma: a retrospective analysis from two high-volume centersJen-Yu Cheng, Yu-Ming Wang, Yen-Hao Chen, et al.
Hepatology International|July 24, 2015
Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patientsJi-Dong Jia, Jin-Lin Hou, You-Kuan Yin, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervixEng-Yen Huang, Hsuan-Chih Hsu, Li-Min Sun, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|May 26, 2007
[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52]Ji-dong Jia, Jin-lin Hou, You-kuan Yin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2019
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 CountriesJin-Lin Hou, Wei Zhao, Changhyeong Lee, et al.
Pageof 37

Showing results (361-370 of 367) with videos related to

Sort By:
Pageof 37
You have reached the last page of results.This site can display upto 367 results.
Acta Pharmacologica Sinica|July 21, 2015
IL-37b gene transfer enhances the therapeutic efficacy of mesenchumal stromal cells in DSS-induced colitis miceWei-qiang Wang, Kui Dong, Lu Zhou, et al.
Hepatobiliary & Pancreatic Diseases International : HBPD INT|June 15, 2016
Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure: a nationwide prospective multicenter study in ChinaJia-Jia Chen, Jian-Rong Huang, Qian Yang, et al.
Japanese Journal of Radiology|February 5, 2026
Intensity-modulated proton therapy for patients with unresectable giant (≥ 10 cm) hepatocellular carcinoma: a retrospective analysis from two high-volume centersJen-Yu Cheng, Yu-Ming Wang, Yen-Hao Chen, et al.
Hepatology International|July 24, 2015
Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patientsJi-Dong Jia, Jin-Lin Hou, You-Kuan Yin, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervixEng-Yen Huang, Hsuan-Chih Hsu, Li-Min Sun, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|May 26, 2007
[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52]Ji-dong Jia, Jin-lin Hou, You-kuan Yin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2019
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 CountriesJin-Lin Hou, Wei Zhao, Changhyeong Lee, et al.
Pageof 37